VLON Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 Apr 2024 @ 16:00):

Stats
Today's Volume	1.11M
Average Volume	0.00
Market Cap	5.39M
EPS	$0 ( 2024-02-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0300
ATR14	$0.0700 (17.50%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-22	Kelly Leanne	Buy	83 333	Stock Option (Right to Buy)
2023-08-10	Szekeres David Leslie	Buy	34 483	Stock Option (Right to Buy)
2023-08-10	Simpson Camilla V	Buy	34 483	Stock Option (Right to Buy)
2023-08-10	Rongen Roelof	Buy	34 483	Stock Option (Right to Buy)
2023-08-10	Baker David Charles	Buy	34 483	Stock Option (Right to Buy)

INSIDER POWER
96.41
Last 43 transactions
Buy: 1 581 385 \| Sell: 149 455

Volume Correlation

Long: 0.44 (neutral)

Short: 0.00 (neutral)

Signal:(48.155) Neutral

Vallon Pharmaceuticals Correlation

10 Most Positive Correlations
AKAN	0.877
RELI	0.861
MAGS	0.856
RKDA	0.842
ATVCU	0.827
APOP	0.82
IKNX	0.82
DHC	0.811
WINT	0.802

10 Most Negative Correlations
MDXH	-0.804

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vallon Pharmaceuticals Correlation - Currency/Commodity

0.58
( weak )

0.52
( weak )

0.00
( neutral )

-0.18
( neutral )

-0.14
( neutral )

-0.47
( neutral )

Vallon Pharmaceuticals Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.710

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.000500

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00280

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.00540

Financial Reports:

No articles found.

Vallon Pharmaceuticals

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.